Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity

T cell-invigorating cancer immunotherapies have near-curative potential. However, their clinical benefit is currently limited, as only a fraction of patients respond, suggesting that these regimens may benefit from combination with tumor-targeting treatments. As oncogenic progression is accompanied...

Descripción completa

Detalles Bibliográficos
Autores principales: Arensman, Michael D., Yang, Xiaoran S., Leahy, Danielle M., Toral-Barza, Lourdes, Mileski, Mary, Rosfjord, Edward C., Wang, Fang, Deng, Shibing, Myers, Jeremy S., Abraham, Robert T., Eng, Christina H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2019
Materias:
PNAS Plus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511047/
https://www.ncbi.nlm.nih.gov/pubmed/31019077
http://dx.doi.org/10.1073/pnas.1814932116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511047/
https://www.ncbi.nlm.nih.gov/pubmed/31019077
http://dx.doi.org/10.1073/pnas.1814932116

Ejemplares similares